The Importance of Newborn Metabolic Screening for G6PD Deficiency

G6PD deficiency is a genetic disorder caused by mutations in the G6PD gene that affects red blood cells. Newborn metabolic screening is essential in identifying babies at risk of complications related to the disorder. Although universal newborn screening for G6PD deficiency is routine in countries where it is prevalent, it is not widely available in other countries, and affected babies may not be diagnosed until they develop symptoms. Trivitron Healthcare is a leading manufacturer and supplier of neonatal G6PD screening assays, including their highly sensitive and specific Neonatal G6PD assay. The assay uses a fluorometric method to measure the activity of the G6PD enzyme in red blood cells and is compatible with most clinical chemistry analyzers, making it convenient for laboratories to incorporate into their routine testing protocols. Early identification of G6PD deficiency allows healthcare providers to closely monitor affected newborns and provide prompt treatment if necessary, reducing the risk of severe complications. Trivitron Healthcare’s commitment to improving newborn screening for G6PD deficiency is part of their broader mission to enhance the quality of healthcare worldwide.